AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Sidoti Events, LLC's Year-End Virtual Investor Conference
Tue 09 Dec 25, 05:48 PMCardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Thu 27 Feb 25, 09:05 PMCardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Thu 20 Feb 25, 09:05 PMCardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ...
Wed 09 Oct 24, 09:53 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -45.87600M | -45.43100M | -41.44100M | -38.70400M | -28.29100M |
| Minority interest | - | - | - | - | - |
| Net income | -45.87600M | -45.43100M | -41.44100M | -37.50600M | -27.74200M |
| Selling general administrative | 14.22M | 12.48M | 13.04M | 13.18M | 11.84M |
| Selling and marketing expenses | - | - | 0.40M | - | - |
| Gross profit | -0.31100M | 0.68M | 0.49M | 0.39M | 0.36M |
| Reconciled depreciation | 0.90M | 0.40M | 0.38M | 0.24M | 0.45M |
| Ebit | -45.87600M | -48.65100M | -45.41200M | -39.90200M | -28.85500M |
| Ebitda | -44.97200M | -48.24700M | -45.01400M | -39.66600M | -28.68900M |
| Depreciation and amortization | 0.90M | 0.40M | 0.40M | 0.24M | 0.17M |
| Non operating income net other | - | - | - | 1.20M | 0.56M |
| Operating income | -48.96000M | -48.65100M | -45.41200M | -39.90200M | -28.85500M |
| Other operating expenses | 49.55M | 49.33M | 45.90M | 40.29M | 29.21M |
| Interest expense | - | - | - | 1.58M | 0.26M |
| Tax provision | - | - | - | - | - |
| Interest income | 3.10M | 3.26M | 3.80M | 1.58M | 0.26M |
| Net interest income | 3.10M | 3.26M | 3.80M | 1.58M | 0.26M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -0.02400M | 0.23M | -1.19800M | -0.54900M |
| Total revenue | 0.59M | 0.68M | 0.49M | 0.39M | 0.36M |
| Total operating expenses | 48.65M | 49.33M | 45.90M | 40.29M | 29.21M |
| Cost of revenue | 0.90M | 0.40M | 0.40M | - | - |
| Total other income expense net | 3.11M | 3.22M | 3.97M | 1.20M | 0.56M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -45.85100M | -45.43100M | -40.80100M | -38.70400M | -28.29100M |
| Net income applicable to common shares | - | - | - | -38.72800M | -28.31500M |
| Preferred stock and other adjustments | - | - | - | 0.02M | 0.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 61.88M | 97.19M | 81.64M | 116.19M | 149.54M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.64M | 2.54M | 2.30M | 5.25M | 4.77M |
| Total liab | 16.50M | 14.24M | 11.90M | 9.85M | 9.13M |
| Total stockholder equity | 45.39M | 82.95M | 69.74M | 106.34M | 140.42M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 7.58M | 7.90M | 7.78M | 5.18M | 0.04M |
| Common stock | 0.00700M | 0.00700M | 0.00400M | 0.00400M | 0.00400M |
| Capital stock | 0.00700M | 0.00700M | 0.00400M | 0.00400M | 0.00500M |
| Retained earnings | -430.03000M | -384.17900M | -339.54100M | -298.10000M | -259.81000M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | 0.00000M | 1.39M | 0.24M |
| Cash | 17.47M | 51.47M | 21.66M | 16.35M | 11.94M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 16.39M | 13.43M | 10.44M | 7.81M | 6.56M |
| Current deferred revenue | - | - | - | - | 4.53M |
| Net debt | -16.63800M | -49.94700M | -19.50600M | -13.63200M | -8.82400M |
| Short term debt | 0.73M | 0.71M | 0.69M | 0.68M | 0.55M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.83M | 1.52M | 2.15M | 2.71M | 3.12M |
| Other stockholder equity | 475.36M | 467.09M | 409.34M | 404.83M | 400.36M |
| Property plant equipment | - | - | - | 1.27M | 0.38M |
| Total current assets | 60.13M | 95.05M | 77.41M | 111.28M | 146.13M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 106.34M | 140.42M |
| Short term investments | 40.83M | 40.28M | 53.17M | 88.92M | 128.88M |
| Net receivables | 0.18M | 0.77M | 0.29M | 0.77M | 0.54M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 8.09M | 4.82M | 1.97M | 1.96M | 1.44M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.05M | 0.03M | -0.06700M | -0.39500M | -0.14200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00400M | 0.00400M |
| Preferred stock total equity | - | - | - | - | 0.00100M |
| Retained earnings total equity | - | - | - | -298.10000M | -259.81000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.55M | 0.07M | 1.28M | 1.39M | 0.24M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.76M | 2.14M | 4.22M | 4.91M | 3.42M |
| Capital lease obligations | 0.83M | 1.52M | 2.15M | 2.71M | 3.12M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 1.39M | 13.73M | 29.65M | 39.04M | -131.24300M |
| Change to liabilities | - | - | - | 1.31M | 0.56M |
| Total cashflows from investing activities | 1.34M | - | - | 38.15M | -131.44800M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 2.58M | 53.78M | 0.00000M | 0.07M | 35.45M |
| Change to operating activities | - | - | - | -1.49200M | -2.29300M |
| Net income | -45.85100M | -45.43100M | -41.44100M | -38.70400M | -28.29100M |
| Change in cash | -34.00000M | 29.82M | 5.31M | 4.40M | -119.03800M |
| Begin period cash flow | 51.47M | 21.66M | 16.35M | 11.94M | 130.98M |
| End period cash flow | 17.47M | 51.47M | 21.66M | 16.35M | 11.94M |
| Total cash from operating activities | -37.92300M | -37.69300M | -30.88700M | -33.82000M | -23.04000M |
| Issuance of capital stock | 0.00000M | 53.41M | 0.00000M | 14.96M | 34.19M |
| Depreciation | 0.90M | 0.40M | 0.40M | 0.24M | 0.45M |
| Other cashflows from investing activities | -0.74400M | - | - | 0.11M | 0.11M |
| Dividends paid | - | - | - | 0.41M | 0.02M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.59M | -0.48400M | 0.48M | -0.23600M | -0.21500M |
| Sale purchase of stock | - | - | - | 0.07M | 35.45M |
| Other cashflows from financing activities | 2.58M | 0.37M | 36.20M | 0.49M | 1.29M |
| Change to netincome | - | - | - | 4.26M | 2.95M |
| Capital expenditures | 0.04M | 0.08M | 0.58M | 0.89M | 0.20M |
| Change receivables | - | - | - | -0.23600M | -0.21500M |
| Cash flows other operating | - | - | - | -1.31100M | -0.10500M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | 4.40M | -119.03800M |
| Change in working capital | 2.18M | 3.17M | 6.57M | -0.38000M | -1.78900M |
| Stock based compensation | 5.69M | 4.76M | 4.51M | 4.26M | 3.23M |
| Other non cash items | -0.84800M | -0.59800M | -0.92100M | 0.77M | 2.03M |
| Free cash flow | -37.96700M | -37.77300M | -31.46900M | -34.71200M | -23.24500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology Inc |
0.15 10.71% | 1.55 | - | - | 190.22 | 2.70 | 109.45 | -3.6608 |
| NVO Novo Nordisk A/S |
1.75 4.17% | 43.75 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.22% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
13.40 3.13% | 441.74 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
9.78 1.58% | 628.73 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
11055 Flintkote Avenue, San Diego, CA, United States, 92121
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark Erlander Ph.D. | CEO & Director | 1960 |
| Mr. James E. Levine | Chief Financial Officer | 1971 |
| Ms. Vicki Kelemen | Chief Operating Officer | NA |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer? | NA |
| Ms. Elizabeth Anderson | VP of Fin. & Admin. | NA |
| Mr. Charles Monahan R.Ph. | Sr. VP of Regulatory Affairs | NA |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer? | 1965 |
| Ms. Elizabeth Anderson | VP of Finance & Administration | NA |
| Ms. Brigitte Lindsay | Senior Vice President of Finance | NA |
| Mr. Charles Monahan R.Ph. | Senior VP of Regulatory Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...